| 產(chǎn)品編號 | bs-3539R-PE-Cy3 |
| 英文名稱 | Rabbit Anti-Paxillin/PE-Cy3 Conjugated antibody |
| 中文名稱 | PE-Cy3標記的樁蛋白Paxillin抗體 |
| 別 名 | Paired box protein Pax 1; PAX 1; PAX1; Paxillin alpha; PXN; PXN protein; FLJ16691; FLJ23042; FLJ16691; PAXI_HUMAN; Paxillin; PXN protein. |
| 規(guī)格價格 | 100ul/2980元 購買 大包裝/詢價 |
| 說 明 書 | 100ul |
| 研究領(lǐng)域 | 腫瘤 免疫學(xué) 信號轉(zhuǎn)導(dǎo) 轉(zhuǎn)錄調(diào)節(jié)因子 激酶和磷酸酶 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應(yīng) | Human, Mouse, (predicted: Rat, Dog, Cow, Horse, Rabbit, ) |
| 產(chǎn)品應(yīng)用 | Flow-Cyt=1:50-200 IF=1:50-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 68kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human Paxillin |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存條件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 產(chǎn)品介紹 |
background: This gene encodes a cytoskeletal protein involved in actin-membrane attachment at sites of cell adhesion to the extracellular matrix (focal adhesion). Alternatively spliced transcript variants encoding different isoforms have been described for this gene. These isoforms exhibit different expression pattern, and have different biochemical, as well as physiological properties (PMID:9054445). [provided by RefSeq, Aug 2011] Function: Cytoskeletal protein involved in actin-membrane attachment at sites of cell adhesion to the extracellular matrix (focal adhesion). Subunit: Binds in vitro to vinculin as well as to the SH3 domain of SRC and, when tyrosine phosphorylated, to the SH2 domain of V-CRK. Isoform beta binds to PTK2/FAK1 but weakly to vinculin. Isoform gamma binds to vinculin but only weakly to PTK2/FAK1. Interacts with GIT1, NUDT16L1/SDOS, PARVA and TGFB1I1. Component of cytoplasmic complexes, which also contain GIT1, ARHGEF6 and PAK1. Interacts with PTK2/FAK1 and PTK2B/PYK2. Binds ASAP2. Interacts with unphosphorylated ITGA4. Interacts with RNF5 and PDCD10. Interacts with NEK3 and this interaction is prolactin-dependent. Interacts with PTK6. Subcellular Location: Cytoplasm, cytoskeleton. Cell junction, focal adhesion. Cytoplasm, cell cortex. Note=Colocalizes with integrins at the cell periphery. Post-translational modifications: Phosphorylated by MAPK1/ERK2. Phosphorylated on tyrosine residues during integrin-mediated cell adhesion, embryonic development, fibroblast transformation and following stimulation of cells by mitogens. Phosphorylation at Ser-244 by CDK5 reduces its interaction with PTK2/FAK1 in matrix-cell focal adhesions (MCFA) during oligodendrocytes (OLs) differentiation. Phosphorylation at Tyr-31 and Tyr-118 by PTK6 promote the activation of RAC1 via CRK/CrKII, thereby promoting migration and invasion. Similarity: Belongs to the paxillin family. Contains 4 LIM zinc-binding domains. Database links: Entrez Gene: 5829 Human Entrez Gene: 19303 Mouse Omim: 602505 Human SwissProt: P49023 Human SwissProt: Q8VI36 Mouse Unigene: 446336 Human Unigene: 18714 Mouse Unigene: 75 Rat Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. Paxillin是一種分子量為68KDa的局部粘附蛋白，參與腫瘤細胞的粘附與轉(zhuǎn)移。主要用于各種惡性腫瘤的研究。 Paxillin 蛋白是胞外基質(zhì)細胞粘附（粘著斑）位點上肌動蛋白-膜附著的細胞骨架蛋白。 Paxillin 在整合蛋白的信號傳導(dǎo)中起著非常重要的作用，整合蛋白介導(dǎo)的細胞骨架的再組織需要，paxillin 酪氨酸殘基的磷酸化。 Paxillin 被粘著斑激酶 (FAK)在其118位的酪氨酸殘基處磷酸化。已經(jīng)證明，paxillin 118位和31位兩個酪氨酸的磷酸化對于MM1癌細胞的遷移是重要的。Paxillin在胚胎發(fā)育、炎癥和多種腫瘤中發(fā)揮作用。 |
| 1、抗體溶解方法 | |
| 2、抗體修復(fù)方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關(guān)于肽鏈的設(shè)計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
